Expert Perspectives & Insights into CAR T-cell Therapy in Relapsed / Refractory Acute Lymphoblastic Leukemia - Episode 19
Role of Multidisciplinary Team & Logistics of CAR T-cell Therapy Administration in the Inpatient or Outpatient Setting
Key opinion leaders address the availability of brexucabtagene autoleucel (brexu-cel) at their institutions and outline procedures for ensuring risk evaluation and mitigation strategy compliance and comprehensive training across multidisciplinary teams.
Video content above is prompted by the following:
- For those who have brexu-cel on-formulary or available at your institution, what processes did you and your team take to ensure REMS compliance and training among multidisciplinary team members?
- Typically, is a physician, pharmacist, nurse, quality coordinator or another member of the team the REMS Authorized Representative?
- At your institution, are patients receiving CAR-T cell Therapy in the outpatient or inpatient setting?
- For those infusing CAR-T cell Therapy in the outpatient setting, how are patients being monitored?
Related Content:
